Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer

被引:2
|
作者
Liu, Yue-E [1 ]
Xue, Xiao-Ying [2 ]
Zhang, Rui [1 ]
Chen, Xue-Ji [1 ]
Ding, Yu-Xia [1 ]
Liu, Chao-Xing [3 ]
Qin, Yue-Liang [1 ]
Li, Wei-Qian [1 ]
Ren, Xiao-Cang [1 ]
Lin, Qiang [1 ,4 ]
机构
[1] Hebei Med Univ, North China Petr Bur Gen Hosp, Dept Oncol, Renqiu, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 2, Dept Radiotherapy, Shijiazhuang, Hebei, Peoples R China
[3] 1 Hosp Shijiazhuang City, Dept Oncol, Shijiazhuang, Hebei, Peoples R China
[4] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China
来源
BMJ OPEN | 2020年 / 10卷 / 10期
关键词
oncology; radiotherapy; respiratory tract tumours; RADIATION-DOSE PRESCRIPTION; CONFORMAL RADIOTHERAPY; ESCALATION; CHEMOTHERAPY; CONSTRAINTS; DOCETAXEL; THERAPY; VOLUME;
D O I
10.1136/bmjopen-2019-036295
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Concurrent chemoradiotherapy with conventional fractionation has been acknowledged as one of the standard treatments for locally advanced non-small cell lung cancer (NSCLC). The radiotherapy dose of 60 Gy is far from enough for local tumour control. Due to this fact, hypofractionated radiotherapy can shorten the total treatment duration, partially counteract the accelerated repopulation of tumour cells and deliver a higher biological effective dose, it has been increasingly used for NSCLC. In theory, concurrent hypofractionated chemoradiotherapy can result in an enhanced curative effect. To date, the vast majority of radiotherapy prescriptions assign a uniform radiotherapy dose to all patients. However this kind of uniform radiotherapy prescription may lead to two consequences: excess damage to normal tissues for large tumours and insufficient dose for small tumours. Our study aims to evaluate whether delivering individualised radiotherapy dose is feasible using intensity-modulated radiotherapy. Methods and analysis Our study of individualised radiotherapy is a multicenter phase II trial. From April 2019, a total of 30 patients from three Chinese centres, with a proven histological or cytological diagnosis of inoperable NSCLC, will be recruited. The dose of radiation will be increased until one or more of the organs at risk tolerance or the maximum dose of 69 Gy is reached. The primary end point is feasibility, with response rates, progression-free survival and overall survival as secondary end points. The concurrent chemotherapy regimen will be docetaxel plus lobaplatin. Ethics and dissemination The study has been approved by medical ethics committees from three research centres. The trial is conducted in accordance with the Declaration of Helsinki. The trial results will be disseminated through academic conference presentations and peer-reviewed publications.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Oesophageal Toxicity and Hypofractionated Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer
    Tho, L. M.
    Mahmood, R.
    Leitch, M.
    Brisbane, I.
    Kakumanu, S.
    Mohammed, N.
    CLINICAL ONCOLOGY, 2009, 21 (01) : 74 - 74
  • [2] Isotoxic hypofractionated radical radiotherapy for non-small cell lung cancer
    Wills, L.
    Hudson, E.
    Button, M.
    Fenwick, J.
    Macbeth, F.
    Lester, J.
    LUNG CANCER, 2007, 57 : S11 - S11
  • [3] Concurrent chemoradiotherapy in non-small cell lung cancer
    O'Rourke, Noelle
    Roque i Figuls, Marta
    Farre Bernado, Nuria
    Macbeth, Fergus
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (06):
  • [4] Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
    Tell, Roger
    Sederholm, Christer
    Klintenberg, Claes
    Franksson, Lars
    Branden, Eva
    Hillerdal, Gunnar
    Lonn, Ulf
    Linden, Carl-Johan
    Ewers, Sven-Borje
    Lamberg, Kristina
    Mrazek, Eva
    Loden, Britta
    Sjogren, Anders
    Linne, Thomas
    Friesland, Signe
    Sirzen, Florin
    ANTICANCER RESEARCH, 2008, 28 (5B) : 2851 - 2857
  • [5] Concurrent chemoradiotherapy with Gemcitabine for locally advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study
    Athanasiou, E
    Cyrgias, G
    Boinis, K
    Samantas, E
    Christodoulidou, M
    Tamvaki, F
    Panoussaki, E
    ANNALS OF ONCOLOGY, 1998, 9 : 97 - 97
  • [6] IDEAL CRT: ISOTOXIC DOSE ESCALATION AND ACCELERATION IN LUNG CANCER CHEMORADIOTHERAPY - A PHASE I/II TRIAL OF CONCURRENT CHEMORADIATION WITH DOSE-ESCALATED RADIOTHERAPY IN PATIENTS WITH STAGE II OR STAGE III NON-SMALL CELL LUNG CANCER
    Landau, David B.
    Khan, Iftekhar
    Ngai, Yenting
    Hughes, Laura L.
    Miles, Elizabeth
    Wilkinson, Dean
    Parsons, Emma
    Mayles, Philip
    Mayles, Helen
    Bates, Andrew T.
    Mohammed, Nazia
    Hicks, Jonathan
    Harden, Susan
    Illsley, Marianne
    Garcia, Angel
    Malik, Zafar
    Hughes, Simon
    Spicer, James
    Baker, Angela
    Wells, Paula
    Laurence, Virginia
    Fenwick, John
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S190 - S190
  • [7] Preliminary results of the prospective randomized phase III trial of the induction chemotherapy and the concurrent chemoradiotherapy for the locally advanced non-small cell lung cancer
    Eun, LJ
    Kyung, CE
    Hoon, KJ
    Sang-Wook, L
    Sang-We, K
    Cheolwon, S
    Shin, LJ
    Cho, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S402 - S402
  • [8] Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer
    Lin, Steven H.
    Lin, Heather Y.
    Verma, Vivek
    Xu-Welliver, Meng
    Thall, Peter F.
    Yao, Luyang
    Kim, Peter Y.
    Gombos, Dan S.
    Kawedia, Jitesh
    Komaki, Ritsuko
    Gomez, Daniel R.
    Nguyen, Quynh-Nhu
    O'Reilly, Michael S.
    Lu, Charles
    Fossella, Frank, V
    Skoulidis, Ferdinandos
    Zhang, Jianjun
    Tsao, Anne S.
    Heymach, John, V
    Blumenschein, George R.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [9] Sequential Chemoradiotherapy with Accelerated Hypofractionated Radiotherapy Compared to Concurrent Chemoradiotherapy with Standard Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
    Zhu, Zheng-Fei
    Ma, Hong-Lian
    Fan, Min
    Sao, Yong
    Zhuang, Ting-Ting
    Chen, Ming
    Jiang, Guo-Liang
    Fu, Xiao-Long
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2014, 13 (03) : 269 - 275
  • [10] Long-term Results of a Phase I/II Trial of Nelfinavir with Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
    Rengan, R.
    Mick, R.
    Pryma, D. A.
    Lin, L. L.
    Plastaras, J.
    Simone, C. B., II
    Gupta, A.
    Evans, T. L.
    Stevenson, J.
    Langer, C.
    Kucharczuk, J.
    Friedberg, J. S.
    Lam, S.
    Patsch, D.
    Hahn, S. M.
    Maity, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S19 - S19